 |
Prospector
Profile
3-12-005
|
| |
| Allos Therapeutics, Inc. |
NAICS |
541710 |
| 11080 Circlepoint Road, Suite 200
Westminster, CO 80020 |
Description |
Biotechnology |
| (303) 426-6262 |
Employees |
66 |
| http://www.allos.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-39.3700 |
| |
Assets |
(mil) |
61.4600 |
| |
Liability |
(mil) |
8.8800 |
| |
(for the year ended 2007-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Allos Therapeutics, Inc., reported a net loss of $39,369,599 for the year ended December 31, 2007, higher than the reported net loss of $30,212,470 in 2006 and $20,136,588 in 2005. As a result of its recurring losses, the Company has an accumulated deficit of $247,928,975 for fiscal year 2007. The Company also used cash for operating activities of $30,823,420 for fiscal year 2007, higher than the $25,146,840 in 2006 and $17,734,900 in 2005.
|
| |
|
Intellectual Property:
In December 2002, the Company entered into a license agreement with Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute, as amended, under which it obtained exclusive worldwide rights to a portfolio of patents and patent applications related to PDX (pralatrexate) and its uses. The portfolio currently consists of two issued patents in the U.S., one granted patent application in Europe, and pending patent applications in the U.S., Canada, Europe, Australia, Japan, China, Brazil, Indonesia, India, South Korea, Mexico, Norway, New Zealand, the Philippines, Singapore, and South Africa. In December 2004, the Company also entered into an agreement with the University of Colorado Health Sciences Center, the University of Salford and Cancer Research Technology, under which the Company obtained exclusive worldwide rights to intellectual property surrounding a proprietary molecule known as RH1. [SEC Filing 10-K 02-27-08]
|
| |
|
Description:
Allos Therapeutics, Inc., engages in the development and commercialization of small molecule drugs for cancer treatments in the United States.
|
| |
|
Officers:
Paul L. Berns (Pres. & CEO); Pablo J. Cagnoni, M.D. (SVP & Chief Medical Officer); James V. Caruso (EVP & Chief Commerical Officer); Marc H. Graboyes (SVP, Gen. Counsel & Sec.); David C. Clark (VP-Finance & Treas.)
|
| |
|
Auditor:
PricewaterhouseCoopers LLP
|
| |
|
Securities:
Common Stock Symbol ALTH; NasdaqGM; 67,837,907 common shares outstanding as of February 20, 2008.
|
| |
| |
| |
| return to main page |
|
|
